Randox Presents Future of Diagnostic Technology
|
By LabMedica International staff writers Posted on 21 May 2023 |

Randox Laboratories (Crumlin, UK) is showcasing its extensive range of innovative products that are revolutionizing healthcare at the 2023 EuroMedLab Congress.
At EuroMedLab Rome 2023, Randox is introducing the new Acusera third-party controls designed for comprehensive test menu consolidation in laboratory internal quality control. These third-party controls are "true," meaning they are not biased towards or optimized for any specific reagent, method, or instrument, and hence offer an objective assessment of performance. Notably, several Acusera controls are produced using 100% human materials, mimicking a patient sample's behavior and thus providing an accurate reflection of the test system's performance.
Also on display at the industry event is Randox's Vivalytic, an all in one molecular diagnostic solution. This compact benchtop platform consolidates the complete molecular workflow, including extraction, PCR amplification, and detection. The unique multiplex Biochip Technology from Randox powers the Vivalytic, yielding multiple results from a single patient sample. The biochip detection system based on a chemiluminescent signal, which is the emission of light without heat from a chemical reaction. Each biochip is pre-engineered with spatially distinct testing regions (DTRs), each representing an individual test. Each DTR can be occupied with oligonucleotides specific to a pathogen or target of interest, allowing the high-plex capabilities of the Biochip Technology to eliminate the need for running multiple, time-consuming, and sample-intensive assays.
Randox is holding live demonstrations of ACUSERA 24•7 Interlaboratory Data Management which provides instant access to an unrivalled range of features including QC multi-rules, interactive charts, live peer group data, automatic calculation of Measurement Uncertainty & Sigma Metrics & a unique dashboard interface, all designed to speed up the review process and provide at-a-glance performance assessment. Randox is also demonstrating RIQAS (Randox International Quality Assessment Scheme which is used by more than 55,000 laboratory participants in 134 countries and accredited to ISO 17043. As a result, Randox has RIQAS users on every continent who are registered for one or more of its 36 flexible EQA programs, utilizing the available data to ensure the quality and reliability of their results.
ACUSERA 24•7 Interlaboratory Data Management, a feature-rich platform offering QC multi-rules, interactive charts, live peer group data, automatic calculation of Measurement Uncertainty & Sigma Metrics & a unique dashboard interface. All these features are designed to expedite the review process and provide at-a-glance performance assessment. Further, Randox is also demonstrating its RIQAS (Randox International Quality Assessment Scheme), an ISO 17043-accredited scheme employed by over 55,000 lab participants across 134 countries. Thanks to its global footprint, Randox has RIQAS users in every continent who are registered for one or more of its 36 flexible EQA programs, thereby leveraging available data to assure the quality and dependability of their results.
Related Links:
Randox Laboratories
Latest EUROMEDLAB 2023 News
- DIESSE Diagnostica Unveils CHORUS EVO Immunochemistry Analyzer
- LGC Clinical Diagnostics Demonstrates Lab Solutions and Processes to Enhance QC Efficiencies
- LumiraDx Demonstrates Fast, High Performance, Portable POC Diagnostic Solution
- Thermo Fisher Presents Latest Solutions in Laboratory Equipment and Technology
- Beckman Coulter Unveils New DxI 9000 Access Immunoassay Analyzer
- STAGO sthemO and sthemE Product Ranges Make World Premiere
- Sansure Biotech Demonstrates iPonatic III Portable Molecular Workstation
- Greiner Bio-One Presents Complete Concept of Digitalized Sample Collection Process
- BioPerfectus Showcases SAW-48 Automated Nucleic Acid Workstation
- Menarini Introduces PRIME MDx All-in-One Molecular Diagnostics Solution
- Werfen Showcases Latest Innovations in Specialized Diagnostics
- Binding Site Showcases Optilite System for Special Protein Testing
- Sebia Presents Innovative Solutions for Screening and Diagnostics
- DiaSorin Showcases Latest Assays and Reagents for In-Vitro Diagnostics
- Abbott Introduces GLP Systems Track Laboratory Automation Solution
- QuidelOrtho Highlights Innovative Point-of-Care Diagnostic Solutions
Channels
Clinical Chemistry
view channel
Blood Test Detects Testicular Cancer Missed by Standard Markers
Testicular cancer most often affects adolescents and young adults and is highly treatable when found early. Diagnosis can be difficult when tumors do not produce sufficient levels of standard blood-based... Read more
Routine Blood Tests Identify Biomarkers Linked to PTSD
Post-traumatic stress disorder (PTSD) is associated with a range of chronic physical health conditions and affects multiple organ systems. Clinical laboratories routinely measure blood analytes that reflect... Read moreMolecular Diagnostics
view channel
Portable Test Detects Tuberculosis from Tongue Swabs in 30 Minutes
Despite decades of effective drug regimens, tuberculosis remains the leading cause of death from an infectious disease, driven in part by limited access to accurate, rapid testing. Conventional diagnostics... Read more
Blood Test Receives FDA Breakthrough Status to Differentiate Schizophrenia and Bipolar Disorder
Differentiating schizophrenia from bipolar I disorder in symptomatic patients is challenging because early presentations often overlap. Current diagnostic pathways rely heavily on subjective assessments... Read more
Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions
Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
Sepsis remains a time-critical condition in which rapid risk assessment is often hindered by reliance on centralized laboratory testing. The global burden is substantial, with an estimated 166 million... Read more
Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
Accurate laboratory diagnosis of early Lyme disease remains challenging because serologic responses may be limited soon after infection. Missed detection at this stage can delay evaluation and management... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more
Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read moreTechnology
view channel
Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
Risk stratification for breast cancer remains imprecise, as population-based models and breast density can over- or underestimate individual risk, potentially leading to over- or under-screening.... Read more








